Introduction: HIT is caused by platelet-activating IgG that recognize multimolecular
| INTRODUC TI ON
Immune heparin-induced thrombocytopenia (HIT) is caused by platelet-activating antibodies that recognize multimolecular complexes of a cationic protein, platelet factor 4 (PF4), bound either to heparin or to platelet-associated polyanions. [1] [2] [3] An important feature of HIT is the high sensitivity (≥97%) of PF4-dependent immunoassays for detecting pathogenic antibodies, 4, 5 in contrast to the much lower sensitivity of platelet antibody testing for other immune-mediated thrombocytopenic disorders, such as idiopathic thrombocytopenic purpura [6] [7] [8] or "classic" (non-HIT) drug-induced immune thrombocytopenia. 9, 10 We have previously reported that PF4-dependent enzyme immunoassays (EIAs) and the platelet serotonin-release assay (SRA) are generally positive at the onset of the HIT-related platelet count fall, including during the early phase of the platelet count decline when HIT would not even be suspected. 11, 12 We have proposed 13 that the high sensitivity of serum/plasma-based assays for HIT antibodies may have implications for the pathogenesis of HIT; for example, significant levels of free (unbound) HIT antibodies might be required to produce the dynamic conditions essential to form multimolecular PF4-polyanion complexes on platelet surfaces needed to engage and crosslink platelet FcγIIa receptors, resulting in Fc receptor-mediated platelet activation characteristic of HIT. [14] [15] [16] We capitalized on the availability of archived plasma samples from a clinical trial of heparin thromboprophylaxis to examine whether early detectability of HIT antibodies is also seen with an automated, rapid immunoassay, known as the latex immunoturbidimetric assay or LIA. To our knowledge, studies using serial plasma samples during acute seroconversion have not been reported using this assay. The LIA is performed on a coagulation instrument (ACL TOP ® Family, Instrumentation Laboratory), and thus, plasma, rather than serum, is used for testing. 17 As most testing for HIT is performed using serum, the availability of these well-characterized plasma samples provided us a unique opportunity to evaluate LIA reactivity associated with HIT seroconversion.
Given the potential for increased use of this assay to provide realtime, on-demand testing for HIT antibodies 18, 19 -including incorporation into real-time Bayesian diagnostic analysis 20 -we sought to determine the changes in LIA reactivity during acute seroconversion and, particularly, whether assay positivity occurs during the earliest phase of HIT, at a time when the platelet count has begun to decline but usually too early for a diagnosis of HIT to be contemplated.
During the study, we became aware of one study patient who had a high clinical probability of HIT, and who tested EIA-positive. However, this patient had tested negative in the platelet serotonin-release assay (SRA) and, thus, was previously considered by our group not to have had HIT. In recent years, the concept of SRA-negative HIT has been proposed, [21] [22] [23] in which subthreshold levels of heparin-dependent platelet-activating antibodies (by SRA) can be detected using modifications to platelet activation assays such as addition of PF4 24, 25 aimed to increasing test sensitivity. Therefore, we investigated whether this patient met clinical and laboratory criteria for SRA-negative HIT. As serial plasma samples were available for this patient, we also studied the LIA seroconversion profile of this patient with putative SRA-negative HIT.
| PATIENTS AND ME THODS

| Archived blood samples from clinical trial
Archived plasma samples were available from a clinical trial of heparin thromboprophylaxis. 26 We have previously tested these plasma samples by SRA, 27 in-house IgG-specific EIA, 28 commer- for SRA-negative HIT).
Permission was received from the Hamilton Integrated Research
Ethics Board to perform these studies (#1288-T). First day that positive SRA was observed.
| Definitions of HIT
e Venogram report showed "valve clot in superficial femoral vein".
| Patient samples studied
Although many of the archived plasma samples had been expended during these and other studies, we were able to evaluate remaining samples available from each of the following patients groups for this study: (a) classic (standard) definition of thrombocytopenia, n = 5;
(b) proportional thrombocytopenia, n = 8 (with six patients meeting >50% fall and two patients with 30.0%-49.9% platelet count fall, and with none of these eight patients attaining a platelet count nadir less than 150 × 10 9 /L); (c) blunted platelet count recovery, n = 4; and (d) subclinical seroconversion, n = 2. In addition, we had available serial plasma samples from a patient with (e) putative SRA-negative HIT (see next section).
| Investigations for SRA-negative HIT
We used the following criteria for SRA-negative HIT
24
: (a) high probability 4Ts score and PF4-dependent EIA > 1.00 optical density (OD) units or intermediate probability 4Ts score and PF4-dependent EIA > 2.00 units; and (b) SRA-negative (including on repeat testing) but positive in a PF4-enhanced platelet activation assay. We used a PF4-enhanced SRA 25 in which the standard SRA 27 is performed with the addition of PF4 (50, 100 µg/mL) rather than unfractionated heparin. We defined a positive PF4-SRA as one that showed increase by 20% or more of serotonin release in the presence of PF4 (vs the buffer control), that is, the same magnitude of increase in serotonin release that defines a positive test in the (classic) SRA. 27 To evaluate thromboprophylaxis trial patients for possible SRA-negative HIT, we identified all EIA-positive, SRA-negative patients who exhibited 30% or greater declines in the platelet count beginning on or after day 5 of heparin therapy.
| Latex Immunoturbidimetric Assay (LIA)
Although classified as an immunoassay, the LIA differs from most were performed using plasma anticoagulated with sodium citrate.
| Timing of LIA vs EIA-GAM seroconversion
For patients with available/informative blood samples, we compared the timing of seroconversion between the LIA and the commercial Hospital is a regional trauma center that also has large medical, cardiology, cardiac surgery, and vascular surgery patient populations). was also positive in the patient recognized as having SRA-negative HIT (discussed subsequently in section "SRA-negative HIT").
| RE SULTS
| LIA reactivities in SRA-positive archived plasma samples
For 13 of the 20 patients shown in Table 1 , a LIA result was available from a plasma sample obtained either on the same day the platelet count began to fall (n = 9), or if not available on the first day of platelet count fall, either one (n = 3) or two (n = 1) days prior to the onset of platelet count fall; for the other seven patients, the available plasma samples were from days after the onset of the HIT-related platelet count fall had already occurred, and thus, LIA status at the onset of the HIT-related platelet count fall could not be determined.
We found that for all 13 evaluable patients, the LIA test was positive at (or shortly before) the onset of the HIT-related platelet count fall (median value, 4.0 U/mL [range, 1.0-18.1]), as were the other assays we performed (SRA, two different EIAs). Thus, as we have reported previously for both the EIA 11 and the SRA, 12 the LIA also is positive at the beginning of the HIT-related platelet count fall. /L (58.9% fall); pulmonary embolism was diagnosed on postoperative day 11, and the patient was treated with therapeutic-dose UFH. HIT was not clinically suspected. During subsequent HIT-related research studies, the patient was not believed to have had HIT, as the SRA was negative. However, during the evaluation of the LIA, the high probability clinical picture, as well as the seroconversion by four immunoassays (two IgG-specific EIAs, with the McMaster in-house EIA indicated by the asterisk [*], a polyspecific EIA, as well as the LIA), prompted investigations for SRA-negative HIT. We found that the day 8 plasma sample yielded a positive PF4-SRA (37% serotonin release at 100 µg/ mL PF4; 0% release with the addition of 100 U/mL heparin), confirming a diagnosis of SRA-negative HIT. EIA-G, enzyme immunoassay that detects IgG class antibodies; EIA-GAM, enyzme immunoassay that detects IgG, IgA, and/or IgM class antibodies (polyspecific); LIA, latex immunoturbidimetric assay; PF4, platelet factor 4; PTT, partial thromboplastin time; sec, seconds; SRA, serotonin-release assay; UFH, unfractionated heparin; U, units 
| LIA Seroconversion
| Timing of LIA vs EIA-GAM seroconversion
| Seroconversion-clinical timelines: representative cases
| SRA-negative HIT
| Distribution of trial results vs comparator HIT populations
| D ISCUSS I ON
We describe a study of LIA seroconversions in patients with serial plasma samples obtained in a historic clinical trial of post-hip replacement heparin thromboprophylaxis. 26 We found that the LIA tested positive in all 19 SRA-positive patients identified in our thromboprophylaxis trial for which available plasma allowed for LIA testing. This high test sensitivity is consistent with our previous evaluation of the LIA, in which we reported a sensitivity of 97.4%
(152/156; 95% CI, 93.6%-99.3%), 20 and which remained similarly high after we extended our evaluation to a greater number of consecutive SRA-positive patients identified at our institution, as shown in Figure 4 (174/179, 97.2%; 95% CI, 93.6%-98.8%). We also found that the timing of LIA seroconversion was similar to that of the polyspecific EIA-GAM, another PF4-dependent immunoassay with high sensitivity for HIT. Moreover, for all evaluable patients, the LIA was already positive at (or shortly before) the onset of the HIT-related platelet count fall, a finding that mirrors what we have reported for the EIA 11 and SRA.
12
The sensitivity of the LIA for HIT might be similar to that for the SRA, given that some patients with HIT may test SRA-negative, that is, so-called "SRA-negative HIT." Indeed, we identified such a patient in our study (Figure 3 ). This patient, who had a high 4Ts
score and who tested EIA-positive, demonstrated LIA seroconversion. Interestingly, this patient's LIA reached its maximal value (5.5) on the same day the platelet count began to fall. This patient also showed platelet count recovery with continued heparin exposure, a phenomenon that we have reported in some patients with HIT in whom heparin is continued. units. 35 It is important for clinicians to be aware of this important difference between the LIA and EIAs; otherwise, there is a risk of a clinician discounting a "weak" LIA test result as being unlikely to be HIT, whereas we found that approximately one-third of patients with confirmed HIT had "weak" LIA results (between 1.0 and 4.9 U/mL).
In conclusion, our study evaluating LIA seroconversion profiles using archived plasma samples from patients with HIT identified in a historic post-hip replacement surgery trial has shown that positive LIA test results are present at the onset of HIT-related platelet count fall. Further, our study identified a single patient who met criteria for SRA-negative HIT; this patient also demonstrated LIA seroconversion, indicating that LIA testing may be useful for evaluating patients suspected of having SRA-negative HIT. 
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